Are lower MRPs on cancer drugs translating into affordable care? - The HinduPublished - November 06, 2026 01:09 am IST‘For comprehensive cancer care in India, price regulation might not be enough’ | Photo Credit: Getty Images/iStockphotoIn a move to make cancer treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing the price of nearly 900 cancer medicine brands by up to 70%-93%. However, for comprehensive cancer care in India, price regulation might not be enough. Are lower MRPs on cancer drugs translating into affordable care? Indu Bhushan and K.M. Gopakumar discuss the question in a conversation moderated by Bindu Shajan Perappadan.Indu Bhushan is bureaucrat, economist and the first CEO of Ayushman Bharat; K.M. Gopakumar is legal adviser, senior researcher and public health expertPublished - November 06, 2026 01:09 am ISTSign in to unlock member-only benefits!Access 10 free stories every monthSave stories to read laterAccess to comment on every storySign-up/manage your newsletter subscriptions with a single clickGet notified by email for early access to discounts & offers on our products${ ind + 1 } ${ device }Last active - ${ la }